Oculis Holding AG announced it will present its neuroprotective drug candidate Privosegtor at the Clinical Trials at the Summit 2026 in Las Vegas. Privosegtor, designed to treat optic neuritis and other optic neuropathies, has shown promising Phase 2 results and received Breakthrough Therapy and PRIME designations from the FDA and EMA. The company is advancing the PIONEER registrational trials to seek approval for this first potential therapy to prevent vision loss from optic nerve damage. This presentation highlights Oculis' progress toward addressing significant unmet medical needs in neuro-ophthalmology.
Intellistake Technologies Corp. celebrates its first year as a decentralized AI and blockchain company, achieving operational milestones including enterprise AI contracts, validator infrastructure on a decentralized network, and launching the Austen ...
Nokia has introduced an agentic AI framework within its Network Services Platform (NSP) to enhance trust-based AI operations for IP networks. This framework allows network operators to deploy AI agents that operate with real-time, accurate network da...
Fermi Inc. shares surged 22.6% following a proxy campaign by co-founder Toby Neugebauer seeking board expansion, new director elections, and a strategic review including potential sale or merger. The campaign highlights Project Matador, an AI power a...
Robin Energy Ltd. (RBNE) shares surged nearly 18% overnight following heightened tensions in the Middle East, particularly after Iran's retaliatory strikes on U.S. bases. The Strait of Hormuz, a vital oil passage, is at the center of these tensions, ...
Martin Shkreli forecasted that Meta Platforms might acquire AI startup Anthropic in a "down exit" due to mounting operational issues, public backlash, and regulatory hurdles. Anthropic faces criticism over policy decisions and data retention practice...
